Lucid Diagnostics

Lucid Diagnostics FCF per Share

The Free Cash Flow per Share of Lucid Diagnostics (LUCD) as of Oct 17, 2026 is -0.46 USD. In the previous year, Free Cash Flow per Share was -0.78 USD — a change of -41.00% (higher).

FCF per Share

-0.46USD

YoY

-41.00%

Last updated:

Free Cash Flow per Share of Lucid Diagnostics is 2025 -0.46 USD. Free Cash Flow per Share of Lucid Diagnostics was 2024 -0.78 USD. It decreases by -41.00% higher compared to the previous year.

The Lucid Diagnostics FCF per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF per Share
Date
FCF per Share
Jan 1, 2018
-0.03 USD
Jan 1, 2019
-0.06 USD
Jan 1, 2020
-0.18 USD
Jan 1, 2021
-0.53 USD
Jan 1, 2022
-0.82 USD
Jan 1, 2023
-0.79 USD
Jan 1, 2024
-0.78 USD
Jan 1, 2025
-0.46 USD
The Lucid Diagnostics FCF per Share history
YEARFCF per ShareYoY
-0.46USD-41.00%
-0.78USD-1.91%
-0.79USD-3.43%
-0.82USD+54.39%
-0.53USD+202.45%
-0.18USD+174.86%
-0.06USD+128.70%
-0.03USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Lucid Diagnostics Stock analysis

What does Lucid Diagnostics do? Lucid Diagnostics Inc, headquartered in New York City, is a commercial-stage medical diagnostics technology company focused on gastroesophageal reflux disease (GERD) and esophageal cancer prevention. The company, listed on October 14, 2021, employs 82 full-time staff and offers EsoCheck, a noninvasive capsule device for esophageal cell sampling, and EsoGuard, a DNA assay for detecting precancerous conditions. It is developing EsoCure, an ablation device for treating dysplastic Barrett's esophagus to prevent progression to lethal esophageal adenocarcinoma (EAC). Lucid Diagnostics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Lucid Diagnostics stock

Free Cash Flow per Share of Lucid Diagnostics is -0.46 USD in 2025.

Free Cash Flow per Share of Lucid Diagnostics changed from -0.78 USD to -0.46 USD, representing a -41.00% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow per Share Lucid Diagnostics since 2006 – with annual values, charts, and detailed analysis.

FCF per share measures the free cash flow allocated to each outstanding share. It is a key metric for assessing shareholder value creation.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Lucid Diagnostics

All Key Metrics — Lucid Diagnostics